The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease (Q28540925)
Jump to navigation
Jump to search
scientific article (publication date: 2014)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease |
scientific article (publication date: 2014) |
Statements
The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease (English)
0 references
Richie Khanna
1 reference
Allan C Powe
1 reference
Yi Lun
1 reference
Rebecca Soska
1 reference
Jessie Feng
1 reference
Rohini Dhulipala
1 reference
Michelle Frascella
1 reference
Anadina Garcia
1 reference
Lee J Pellegrino
1 reference
Su Xu
1 reference
Nastry Brignol
1 reference
Matthew J Toth
1 reference
Hung V Do
1 reference
David J Lockhart
1 reference
Brandon A Wustman
1 reference
Kenneth J Valenzano
1 reference
2014
0 references
9
0 references
7
0 references
e102092
0 references
18 July 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference